Beta 3 adrenergic agonists

The compound of claim 18 wherein:

• m is 2;
• n is 0 or 1;
• A1, A2 and A3 are carbon;
• Het is at the ortho-position relative to X and is thien-2-yl wherein said thien-2-yl moiety is optionally substituted with CN or CH3;
• R1, R2 and R3 are H;
• R4 and R5 are independently H or methyl at each occurrence;
• the 6,5 ring system is connected to the (CR4R5)2 moiety at the 3-position of the 6,5 ring system;
• R6 is independently at each occurrence methyl;
• R7 is at the 6- or 7-position of the 6,5 ring system to which it is attached and is selected from H, O(CH2)pR12 or thienyl;
• X is OCH2;
• p is 0 or 1;
• and
• R12 is CONH2, phenyl or pyridyl substituted once with CONH2;
• or a pharmaceutical salt thereof.

A compound of the formula:

• wherein:
• m is 1, 2, 3, 4 or 5;
• n is 0, 1 or 2;
• A1, A2 and A3 are carbon;
• each D is either carbon or nitrogen provided that only one D can be nitrogen;
• each D′ is either carbon or nitrogen provided that only one D′ can be nitrogen;
• and further provided that the total number of D and D′ that are nitrogen must be two and only two;
• Het is thien-2-yl optionally substituted with CN or CH3;
• R1 and R2 are H;
• R3 is H or C1-C6 alkyl;
• R4 and R5 are independently at each occurrence H or C1-C6 alkyl;
• or R4 and R5 combine with the carbon to which they are both attached to form a C3-C7 carbocyclic ring;
• R6 is independently at each occurrence halo, hydroxyl, cyano, C1-C6 alkyl, C1-C4 haloalkyl or C1-C6 alkoxy;
• R7 is H, CO2R8, CONR8R8, CH═CHR9, CH2CH2R9, NR8R8, NR8SO2R8, O(CR10R11)pR12, O(CR10R11)qR13, SO2R8, SO2NR8R8, optionally substituted phenyl where when substituted has one to three groups independently selected from halo, hydroxy, oxo, cyano, nitro, phenyl, benzyl, C1-C6 alkyl, C1-C4 haloalkyl, C1-C6 alkoxy, COR17, CONR17R17, CO2R17, NR17R17, NR17COR18, NR17SO2R18, OCOR18, OCO2R17, OCONR17R17, SR17, SOR18, SO2R18 and SO2(NR17R17), where R17 is independently at each occurrence H, C1-C6 alkyl, phenyl or benzyl and R18 is independently at each occurrence C1-C6 alkyl, phenyl or benzyl;
• X is OCH2;
• p is , 1, 2 or 3;
• q is 1, 2 or 3;
• R8 is independently at each occurrence H, C1 -C6 alkyl or phenyl;
• R9 is cyano, CO2R14, CONR14R14, CONR14SO2R14, SO2R14 or optionally substituted phenyl where when substituted has one to three groups independently selected from halo, hydroxy, oxo, cyano, nitro, phenyl, benzyl, C1-C6 alkyl, C1-C4 haloalkyl, C1-C6 alkoxy, COR17, CONR17R17, CO2R17, NR17R17, NR17COR18, NR17SO2R18, OCOR18, OCO2R17, OCONR17R17, SR17, SOR18, SO2R18 and SO2(NR17R17), where R17 is independently at each occurrence H, C1-C6 alkyl, phenyl or benzyl and R18 is independently at each occurrence C1-C6 alkyl, phenyl or benzyl;
• R10 and R11 are independently at each occurrence H or C1-C6 alkyl;
• R12 is hydrogen, CO2R15, CONR15R15, SO2R15, SO2NR16R16, pyridyl or optionally substituted phenyl where when substituted has one to three groups independently selected from halo, hydroxy, oxo, cyano, nitro, phenyl, benzyl, C1-C6 alkyl, C1-C4 haloalkyl, C1-C6 alkoxy, COR17, CONR17R17, CO2R17, NR17R17, NR17COR18, NR17SO2R18, OCOR18, OCO2R17, OCONR17R17, SR17, SOR18, SO2R18 and SO2(NR17R17), where R17 is independently at each occurrence H, C1-C6 alkyl, phenyl or benzyl and R18 is independently at each occurrence C1-C6 alkyl, phenyl or benzyl;
• R13 is cyano, NR16R16, NR16SO2R16 or OR16;
• R14, R15 and R16 are independently at each occurrence H, C1-C6 alkyl or phenyl;
• or a pharmaceutical salt thereof.